Home » Stocks » SWTX

Springworks Therapeutics, Inc. (SWTX)

Stock Price: $81.03 USD 2.09 (2.65%)
Updated Jan 21, 2021 12:29 PM EST - Market open
Market Cap 3.83B
Revenue (ttm) n/a
Net Income (ttm) -73.06M
Shares Out 42.15M
EPS (ttm) -13.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $81.03
Previous Close $78.94
Change ($) 2.09
Change (%) 2.65%
Day's Open 79.00
Day's Range 76.02 - 84.21
Day's Volume 189,722
52-Week Range 20.44 - 84.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 1 day ago

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, inv...

Other stocks mentioned: BEAM, CRSP, EDIT, NTLA
GlobeNewsWire - 2 weeks ago

STAMFORD, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...

GlobeNewsWire - 1 month ago

STAMFORD, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...

GlobeNewsWire - 1 month ago

STAMFORD, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...

GlobeNewsWire - 2 months ago

- Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors -

PRNewsWire - 2 months ago

DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("SpringWorks") today announced that Jazz Ph...

Other stocks mentioned: JAZZ
GlobeNewsWire - 3 months ago

STAMFORD, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...

Zacks Investment Research - 3 months ago

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

STAMFORD, Conn., Oct. 07, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...

GlobeNewsWire - 3 months ago

STAMFORD, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...

GlobeNewsWire - 3 months ago

Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities

GlobeNewsWire - 3 months ago

STAMFORD, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...

GlobeNewsWire - 4 months ago

STAMFORD, Conn., Sept. 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...

GlobeNewsWire - 4 months ago

Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities

GlobeNewsWire - 5 months ago

– Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors - 

GlobeNewsWire - 5 months ago

STAMFORD, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...

GlobeNewsWire - 5 months ago

STAMFORD, Conn., July 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...

GlobeNewsWire - 6 months ago

Preclinical data presented at the American Association for Cancer Research 2020 Virtual Annual Meeting II

GlobeNewsWire - 6 months ago

STAMFORD, Conn., June 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...

Zacks Investment Research - 7 months ago

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

STAMFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...

GlobeNewsWire - 7 months ago

STAMFORD, Conn., May 26, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for ...

GlobeNewsWire - 8 months ago

- Announced Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 - 

Seeking Alpha - 9 months ago

SpringWorks Therapeutics: View Ahead Of 2020 Catalysts

GlobeNewsWire - 10 months ago

STAMFORD, Conn., March 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. P...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the developme...

The Motley Fool - 1 year ago

The stock climbed after investors saw encouraging signs from a similar program.

GlobeNewsWire - 1 year ago

STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...

GlobeNewsWire - 1 year ago

STAMFORD, Conn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...

GlobeNewsWire - 1 year ago

STAMFORD, Conn., Sept. 24, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...

GlobeNewsWire - 1 year ago

STAMFORD, Conn., Sept. 17, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...

Benzinga - 1 year ago

Springworks Therapeutics, Inc. (NASDAQ: SWTX) made its public debut Friday morning, opening at $24.50 after being priced between $16 and $18 per share.

About SWTX

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neu... [Read more...]

Industry
Biotechnology
IPO Date
Sep 13, 2019
CEO
Saqib Islam
Employees
71
Stock Exchange
NASDAQ
Ticker Symbol
SWTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is 86.00, which is an increase of 6.13% from the latest price.

Price Target
$86.00
(6.13% upside)
Analyst Consensus: Buy